LY4395089
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LY4395089, covering 2026-04-21 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease [Phase 2]